NeuroSense CEO Provides Q1 2023 Update: Phase 2b ALS Trial Achieves 80% Enrollment
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today...
United States United Kingdom Prnewswire Neurosense Therapeutics Ltd Neurosense Therapeutics Ltd Hospital Neuroepigenetics Lab Sense Therapeutics
Source: prnewswire.com